Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. Belite Bio Inc. is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-36.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 13.70 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -34.90% |
| Return on Assets (Trailing 12 Months) | -33.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 23.15 |
| Quick Ratio (Most Recent Fiscal Quarter) | 23.15 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.18 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 31.84M |
| Free Float | 27.61M |
| Market Capitalization | $2.05B |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | -1.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.29% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |